drugset / Trial / NCT02986451
Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This phase II study investigating the efficacy and safety of a combination of biaxin,lenalidomide and dexamethasone in subjects with relapsed/refractory MM.
Timeline
- Start
- 2016-12
- Primary completion
- 2018-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 500 mg | Oral |
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |